Research programme: androgen receptor antagonists - Praecis

Drug Profile

Research programme: androgen receptor antagonists - Praecis

Latest Information Update: 21 Feb 2008

Price : $50

At a glance

  • Originator Praecis Pharmaceuticals
  • Class
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 16 Feb 2007 Praecis Pharmaceuticals has been acquired by GlaxoSmithKline
  • 03 Jul 2002 Preclinical trials in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top